Scancell Holdings plc (LON:SCLP) Insider Martin Diggle Purchases 4,400,000 Shares

Key Points

• Insider Martin Diggle purchased 4,400,000 shares of Scancell Holdings plc at an average price of GBX 10 ($0.13), totaling approximately £440,000 ($584,251.76).
• Scancell stock opened at GBX 10.90 ($0.14) with a 12-month range between GBX 7.26 ($0.10) and GBX 19.75 ($0.26), indicating considerable volatility in its value.
• Scancell is a clinical stage immunotherapy biotech firm focused on developing innovative cancer treatments to address significant unmet needs in the oncology sector.

Scancell Holdings plc (LON:SCLP - Get Free Report) insider Martin Diggle bought 4,400,000 shares of the business's stock in a transaction dated Friday, August 1st. The shares were bought at an average price of GBX 10 ($0.13) per share, with a total value of £440,000 ($591,715.98).

Martin Diggle also recently made the following trade(s):

• On Thursday, August 7th, Martin Diggle purchased 102,236 shares of Scancell stock. The shares were purchased at an average cost of GBX 11 ($0.15) per share, with a total value of £11,245.96 ($15,123.67).
• On Tuesday, May 20th, Martin Diggle acquired 44,944 shares of Scancell stock. The stock was purchased at an average cost of GBX 9 ($0.12) per share, for a total transaction of £4,044.96 ($5,439.70).

Scancell Price Performance

LON SCLP traded up GBX 0.15 ($0.00) on Friday, hitting GBX 11.15 ($0.15). 346,110 shares of the company's stock were exchanged, compared to its average volume of 982,914. Scancell Holdings plc has a 52 week low of GBX 7.26 ($0.10) and a 52 week high of GBX 19.75 ($0.27). The stock has a 50-day moving average of GBX 10.01 and a 200-day moving average of GBX 9.47. The company has a current ratio of 3.42, a quick ratio of 13.01 and a debt-to-equity ratio of -566.79. The stock has a market cap of £115.48 million, a price-to-earnings ratio of -17.09 and a beta of 0.35.

About Scancell

Scancell LSE: SCLP is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers. Scancell has developed a pipeline of ‘off-the-shelf' vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs.